Welcome to Blood Cancer United Newsroom
Get the latest news about how we are creating a world without blood cancers—and improving the quality of life of patients and their families.
January 2021
In the month of January, we have identified 42 peer-reviewed publications that cited support from the leukemia and Lymphoma Society through our variou…
News
LLS TAP announces five new investments supporting next generation immunotherapies
RYE BROOK, N.Y., April 22, 2021 /PRNewswire/ -- The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) today announced five new inves…
News
LLS Statement on Anti-Asian Violence and Discrimination
The Leukemia & Lymphoma Society condemns violence and discrimination against members of the Asian, Asian American, and Pacific Islander community, whi…
News
FDA Approves Isatuximab for Relapsed/Refractory Multiple Myeloma
The U.S. Food and Drug Administration (FDA) approved isatuximab (Sarclisa) in combination with carfilzomib and dexamethasone to treat adult patients w…
News
Everyday Heroes Fight for a Cancer-Free Future
The Leukemia & Lymphoma Society kicks-off 32nd annual Man & Woman of the Year campaign bringing together diverse communities across the country
Board of Trustees - Lehigh Valley
The Lehigh Valley Chapter's Board of Trustees is comprised of distinguished individuals dedicated to LLS's mission to cure leukemia, lymphoma, Hodgkin…
Research
Publication of CPX-351 Clinical Data in 'Blood Advances': Phase 3 Post-Hoc Analyses
March 16, 2021 - CPX-351 (Vyxeos, daunorubicin and cytarabine liposome for injection) is a dual-drug liposomal encapsulation of daunorubicin and cytar…
Research
FDA Approves Vyxeos for Secondary Acute Myeloid Leukemia in Children
DUBLIN, March 30, 2021 - Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced that the U.S. Food and Drug Administration (FDA) approved a revised label f…
Research
Age-Related AML Risk: An Exploration of Hematopoietic Stem Cell Epigenetics
The population of elderly people is increasing both in the United States and worldwide, and this increase presents challenges in addressing the medica…
For all media-related inquiries and interview requests please email
mediarelations@bloodcancerunited.org
A Blood Cancer United representative will respond as soon as possible.
